Daptomycin versus Vancomycin for Empiric Treatment of Methicillin-Resistant S. aureus among Hospitalized Patients: An Institutional Cost-Breakpoint Analysis

dc.contributor.advisorGarey, Kevin W.
dc.contributor.committeeMemberChen, Hua
dc.contributor.committeeMemberCottreau, Jessica M.
dc.contributor.committeeMemberSansgiry, Sujit S.
dc.creatorPham, Jennifer
dc.date.accessioned2018-03-01T17:00:00Z
dc.date.available2018-03-01T17:00:00Z
dc.date.createdMay 2013
dc.date.issued2013-05
dc.date.submittedMay 2013
dc.date.updated2018-03-01T17:00:00Z
dc.description.abstractBackground: Bacteremia caused by methicillin-resistant Staphylococcus aureus is associated with increased hospitalization days, costs, and mortality. Daptomycin was shown to be noninferior to vancomycin in a phase III clinical trial; however the study was limited by low rates of MRSA infection and before the emergence of strains with reduced susceptibility to vancomycin. Purpose: The purpose of this study was to perform a cost-breakpoint analysis comparing daptomycin versus vancomycin as empiric therapy for methicillin-resistant Staphylococcus aureus bacteremia. Methods: Data from a phase III, randomized clinical trial comparing daptomycin to vancomycin was used to build a cost breakpoint model. Costs and clinical outcomes associated with drug purchase, toxicity management, vancomycin-resistance, and likelihood of empiric therapy correctly given to patients with confirmed S. aureus bacteremia were added to the model. The model was then used to assess when daptomycin may be beneficial for empiric treatment. Results: The decision model was able to mimic the results of the phase III clinical trial. Holding other parameters constant, the results showed that empiric treatment correctly directed to S. aureus bacteremia of at least 40% (assumed MIC: 0.5 mcg/ml), a MIC of 1.0 – 1.5 mcg/ml (correct empiric therapy: 30%), or a MIC of 2.0 (correct empiric therapy: 20%), daptomycin was more cost-effective than vancomycin as empiric MRSA bacteremia treatment. Conclusion: With increasing vancomycin MRSA MIC against S. aureus, daptomycin may be an appropriate choice of empiric therapy for suspected bacteremia is certain cases.
dc.description.departmentPharmacy, College of
dc.format.digitalOriginborn digital
dc.format.mimetypeapplication/pdf
dc.identifier.urihttp://hdl.handle.net/10657/2617
dc.language.isoeng
dc.rightsThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).
dc.subjectMethicillin-resistant Staphylococcus
dc.subjectDaptomycin
dc.subjectVancomycin
dc.subjectDecision analysis
dc.subjectCost
dc.titleDaptomycin versus Vancomycin for Empiric Treatment of Methicillin-Resistant S. aureus among Hospitalized Patients: An Institutional Cost-Breakpoint Analysis
dc.type.dcmiText
dc.type.genreThesis
thesis.degree.collegeCollege of Pharmacy
thesis.degree.departmentPharmacy, College of
thesis.degree.disciplinePharmacy Administration
thesis.degree.grantorUniversity of Houston
thesis.degree.levelMasters
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PHAM-THESIS-2013.pdf
Size:
354.66 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description:
No Thumbnail Available
Name:
LICENSE_1.txt
Size:
1.84 KB
Format:
Plain Text
Description: